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ciated with the lower baseline serum HBV DNA levels, HBV DNA
negativity at week 24 and undetectable serum YMDD mutation
at week 12 compared with non-response. Early treatment with
adefovir dipivoxil for the patients with YMDD mutation who had
virological breakthrough and without biochemical breakthrough
can reach for better curative effect.
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Background: Over time, the levels of HBsAg in some chronic HBV
infected individuals declines and is not detectable in the serum.
The purpose of this study was to assess the efﬁcacy of HBV
vaccine in subjects who lost their HBsAg with not seroconverssion
to anti-HBs.
Methods: From April 1993 to December 2007, among 1603 chronic
HBV infected individuals, 34 subjects (22 males, 12 females) be-
came HBsAg negative with no detectable anti-HBs and HBV DNA
in their sera. They received HBV vaccine at 0, 1 and 6 months
(case group). Fifty-two subjects (30 males, 22 females) who were
negative to HBsAg, anti-HBs and anti-HBc received HBV vaccine
like the above schedule (control group). Anti-HBs was assessed
one month of the last dose in these two groups.
Result: The mean age of the case group was 38±12.7 and the
control group was 33.4±8.6 years (p=0.07). The distribution of
sexes between these two groups were equal (p=0.652). The mean
year of follow-up for the case group was 7.6±4.5 years. Anti-HBs
levels ≥10 IU/l was developed in 8 (23.5%) subjects in the case
group and in 45 (86.5%) of the control group (p=0.0001). The
mean anti-HBs levels in the case group was 68±32.66 and in the
control group was 344.6±38.9 IU/l (p=0.00001).
Conclusion: The results show that nearly 24% of chronic HBsAg
positive subjects, who lost their HBsAg responded to hepatitis B
vaccine and the remaining cases need to be followed for occult
HBV infection.
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Background & Aim: Hepatitis B virus (HBV) infection with unde-
tectable levels of hepatitis B surface antigen (HBsAg) is called an
occult infection, which although has been described among sub-
jects with chronic hepatitis C liver disease in the western world,
it’s prevalence and clinical signiﬁcance are still ambiguous in the
Indian subcontinent.
Methods: We investigated HBV-DNA PCR in serum samples of 260
HBsAg negative subjects with chronic HCV-related liver disease,
and 70 apparently healthy volunteers negative for HBsAg and
anti-HCV as control.
Results: Serum samples found positive by at least two indepen-
dent PCR assays were considered HBV DNA positive. HBV-DNA
was detected among 19 HCV-related chronic liver disease (CLD)
patients (7.3%), which was higher (p=0.2) as compared with
the control volunteers (4.3%). It was more frequent (37.5%) in
24 anti- HBs negative/anti-HBc positive patients than in 180
anti-HBs/anti-HBc positive (5%, p<0.05). HCV RNA by qualitative
PCR was signiﬁcantly (p<0.001) higher in occult HBV compare to
non-occult. HCV genotype 1b was predominantly associated with
occult HBV (73%), especially among subjects with hepatocellu-
lar carcinoma (HCC) (p<0.05) as compared to non-occult HBV
cases. Though not signiﬁcant, frequency of occult HBV infection
was higher than healthy controls and HCV 1b genotype was
signiﬁcantly associated in patients with HCC.
Conclusion: This study suggests that in all HBV-endemic areas,
the possibility of occult HBV in patients with HCV should be
considered and HBV-DNA should be performed.
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Objective: To observe the efﬁciency of Thymosin-α1 treatment
in patients with chronic hepatitis B.
Methods: Fifty-six HBeAg-negative and sixty-two HBeAg-positive
patients were randomly divided two groups, received Thymosin-
α1 or Interferon alpha for six months respectively.
Results: At the end of treatment, complete response (CR) oc-
curred in 8 of 26 and 9 of 29 in T-α1 group and in 14 of 30 and
15 of 33 in IFN-α group in HBeAg-negative and HBeAg-positive
patients respectively (p>0.05). After a 6-month follow-up pe-
riod, a CR was observed in 11 of 26 HBeAg-negative and 14 of
29 HBeAg-positive in T-α1 group and in 7 of 30 HBeAg-negative
and 9 of 33 HBeAg-positive patients in IFN-α group (p>0.05).
Compared with the results observed in untreated patients, the
rate of CR was signiﬁcantly higher in IFN-α group at the end of
therapy (p<0.001) and in T-α1 group at the end of follow-up
(p<0.001). Ten of the 12 T-α1 responders experienced sustained
non-detectable HBVDNA after the 6-month treatment period.
Six of the 14 T-α1 non-responders showed delayed response of
non-detectable HBVDNA during the follow-up period. In HBeAg-
positive patients, it is 87.5% and 53.8%. However, the data were
50% and 0%, 59.1% and 0% in IFN-α group, respectively. The rate of
delayed response was signiﬁcantly higher in T-α1 group (p=0.010)
and the rate of ﬂare was higher in IFN-α group (p>0.05) during
the follow-up period.
Conclusion: A 6-months course of T-α1 therapy is effective in CHB
patients with a gradual and more sustained ALT normalization
and HBVDNA loss.
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Objectives: To investigate the genotypic resistance proﬁles in
chronic hepatitis B patients who underwent virological break-
through during adefovire treatment.
Methods: Serum samples and clinical data were collected from
adefovir treated patients (10mg/d) who underwent virological
breakthrough (HBV DNA increase 1log10 copies/ml from the
Nadir). Adefovir genotypic resistance was detected with PCR
product pyrosequencing. HBV genotypes were identiﬁed by phy-
logenetic tree analysis of PCR product di-deoxy sequencing
